Serum soluble interleukin‐2 receptor levels in chronic progressive, stable and steroid‐treated multiple sclerosis

S. Bansil, R. Troiano, S. D. Cook, C. Rohowsky‐Kochan

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

ABSTRACT Serum levels of the soluble interleukin‐2 receptor (sIL‐2R), an indicator of T cell activation, were significantly elevated in chronic progressive MS (CPMS) patients, clinically stable MS patients and in patients with other neurological diseases (OND) as compared to healthy controls. Levels of sIL‐2R in steroid treated CPMS patients were markedly lower than in untreated CPMS patients and were comparable to healthy controls. Thus, systemic T cell activation occurs in MS during clinically stable and progressive disease stages and in other neurological disorders. The ability of oral corticosteroids to depress serum sIL‐2R levels in vivo may be one mechanism by which they exert their therapeutic effect. 1991 Blackwell Munksgaard

Original languageEnglish (US)
Pages (from-to)282-285
Number of pages4
JournalActa Neurologica Scandinavica
Volume84
Issue number4
DOIs
StatePublished - Oct 1991

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Serum soluble interleukin‐2 receptor levels in chronic progressive, stable and steroid‐treated multiple sclerosis'. Together they form a unique fingerprint.

Cite this